NEW YORK--(BUSINESS WIRE)--Aug. 8, 2006--OMRIX Biopharmaceuticals Inc. (“OMRIX” or “Company”) (NASDAQ: OMRI - News), a commercial-stage biopharmaceutical company that develops and markets biosurgical and passive immunotherapy products, today announced financial results for the second quarter ended June 30, 2006.
